EMA Grants Priority Medicines Status for NASH Treatment Drug

If you’ve driven past the gleaming towers of the Texas Medical Center in Houston lately, you’ve likely noticed the same thing doctors in the Galleria’s high-rise clinics have been whispering about for months: a quiet but seismic shift in how we treat one of the most stubborn liver diseases on the planet. That shift just got a major regulatory green light, and it’s about to land squarely in the laps of Houstonians—especially those in neighborhoods like Montrose, where late-night bar crawls and rich Gulf Coast cuisine collide with the realities of metabolic health.

The European Medicines Agency (EMA) recently recommended a new drug called efinopegdutide—developed by pharmaceutical giant GSK—for the treatment of metabolic dysfunction-associated steatohepatitis, or MASH. This isn’t just another entry in the alphabet soup of liver conditions. MASH is the inflammatory, scar-forming stage of fatty liver disease, and it’s silently exploding across Texas, fueled by the same factors that make Houston a culinary mecca: high-calorie diets, sedentary lifestyles, and a diabetes epidemic that’s been creeping through the city’s diverse communities for decades. The EMA’s nod isn’t just a bureaucratic checkbox—it’s a signal that the medical community is finally arming itself against a disease that, until now, had no approved pharmaceutical treatments.

For Houstonians, this news isn’t just clinical. It’s personal. The city’s health landscape is a microcosm of the broader MASH crisis. Harris County’s obesity rate hovers around 35%, and Texas ranks among the top 10 states for diabetes prevalence. The disease doesn’t discriminate, but its impact is uneven. In wealthier pockets like River Oaks, patients might catch MASH early through routine bloodwork at places like Houston Methodist or MD Anderson. But in underserved areas like Third Ward or Kashmere Gardens, where access to primary care is spotty and food deserts are a daily reality, the disease often progresses unnoticed until it’s too late. By the time symptoms like fatigue or abdominal pain appear, the liver is already scarred, and the clock is ticking toward cirrhosis or even liver cancer.

Efinopegdutide isn’t the first drug to target MASH, but it’s the first to show real promise in a field that’s been littered with failures. The drug works by mimicking the effects of two naturally occurring hormones—glucagon-like peptide-1 (GLP-1) and glucagon—that regulate blood sugar and fat metabolism. Think of it as a one-two punch: GLP-1 helps the body utilize insulin more efficiently, while glucagon ramps up fat burning in the liver. In clinical trials, patients taking efinopegdutide saw significant reductions in liver fat and inflammation, and some even experienced a reversal of fibrosis, the scarring that’s the hallmark of advanced MASH. The EMA’s recommendation is based on these results, and while the U.S. Food and Drug Administration (FDA) is still reviewing the drug, the agency has already granted it a “Priority Review” designation, meaning a decision could come as early as this summer.

What does this mean for Houston? For starters, it’s a wake-up call for the city’s healthcare infrastructure. MASH isn’t just a liver disease—it’s a metabolic time bomb, and Houston’s hospitals and clinics are about to be on the front lines. The Texas Medical Center, already a global hub for liver research and transplantation, is likely to become a key player in the rollout of efinopegdutide. Institutions like Baylor College of Medicine and the University of Texas Health Science Center at Houston have been studying MASH for years, and their researchers are already eyeing the drug as a potential game-changer. But the real challenge will be getting it into the hands of the patients who need it most—those in communities where MASH is often diagnosed too late, if at all.

That’s where Houston’s unique cultural and economic landscape comes into play. The city is a patchwork of affluent enclaves and working-class neighborhoods, each with its own relationship to healthcare. In the Energy Corridor, where oil executives and engineers work long hours at desks, MASH is often a silent companion to type 2 diabetes. In the Latino communities of the East End, where traditional diets rich in fried foods and sweets collide with genetic predispositions to liver disease, the stakes are even higher. And in the city’s sprawling suburbs, where car-dependent lifestyles and fast-food chains dominate, the disease is spreading like wildfire among adolescents—a trend that has pediatricians at Texas Children’s Hospital sounding the alarm.

The regulatory progress of efinopegdutide as well shines a light on a broader trend in pharmaceutical innovation: the rise of “dual agonists” like GLP-1/glucagon drugs. These medications are part of a new wave of treatments that target multiple pathways in the body, offering hope for diseases that have long been considered untreatable. For MASH, this is a turning point. Until now, the only “treatment” was lifestyle changes—diet, exercise, weight loss—which, while effective, are notoriously difficult to sustain. Efinopegdutide doesn’t replace those changes, but it could give patients a fighting chance to stick with them. Imagine a Houstonian in their 40s, diagnosed with MASH after years of ignoring their doctor’s warnings about their weight and blood sugar. Instead of facing a grim prognosis, they’re handed a prescription that, combined with a structured diet and exercise plan, could reverse the damage before it’s too late.

But here’s the catch: drugs like efinopegdutide don’t exist in a vacuum. They’re part of a larger ecosystem of care, and in a city as vast and fragmented as Houston, that ecosystem is only as strong as its weakest link. For every patient who can afford to see a hepatologist at a top-tier hospital, there are dozens more who rely on community clinics or, worse, go without care entirely. The rollout of efinopegdutide will test Houston’s ability to bridge these gaps. Will the drug be covered by Medicaid and private insurers? Will primary care physicians in underserved areas be trained to recognize MASH early and prescribe the drug appropriately? And perhaps most importantly, will the city’s public health infrastructure step up to address the root causes of MASH—poor diet, lack of exercise, and the social determinants of health that make these issues so intractable?

There’s also the question of cost. GSK hasn’t announced pricing for efinopegdutide yet, but if it follows the pattern of other specialty drugs, it won’t be cheap. In a city where nearly 20% of residents are uninsured—the highest rate in the country—this could be a major barrier. Advocacy groups like the American Liver Foundation’s Texas chapter are already gearing up for a fight, pushing for policies that ensure the drug is accessible to all, not just those with gold-plated insurance plans. “This isn’t just about a pill,” said a spokesperson for the foundation in a recent statement. “It’s about equity. If we don’t make sure everyone who needs this drug can get it, we’re just papering over the cracks in our healthcare system.”

For Houstonians, the arrival of efinopegdutide is a moment of both hope and reckoning. It’s a reminder that the city’s health challenges are as complex as its freeways, and that solving them will require more than just medical innovation. It will take a concerted effort from hospitals, insurers, policymakers, and community leaders to ensure that this drug—and others like it—reach the people who need them most. And it will take a cultural shift, too. Houston’s love affair with food is legendary, but so is its resilience. If any city can turn the tide on MASH, it’s this one.

The Local Ripple Effect: What Efinopegdutide Means for Houston’s Healthcare Landscape

Houston’s healthcare system is a behemoth, but it’s not monolithic. The city’s hospitals and clinics operate in a delicate balance of competition and collaboration, and the introduction of a drug like efinopegdutide is likely to shake things up. For starters, expect to see a surge in demand for hepatologists—liver specialists who are already in short supply. The Texas Medical Center is home to some of the best in the world, but even they can’t keep up with the projected increase in MASH cases. This could lead to longer wait times for appointments, especially in the city’s safety-net hospitals like Ben Taub, where resources are already stretched thin.

Then there’s the question of diagnostics. MASH is often diagnosed through a combination of blood tests, imaging, and, in some cases, a liver biopsy. But biopsies are invasive, expensive, and not always accessible to patients in underserved communities. The good news is that Houston is at the forefront of developing non-invasive alternatives. Researchers at the University of Texas Health Science Center are working on a blood test that could detect MASH with near-perfect accuracy, and if it pans out, it could revolutionize how the disease is diagnosed and monitored. In the meantime, clinics like Legacy Community Health, which serves many of Houston’s uninsured and underinsured residents, are ramping up their efforts to screen for MASH during routine check-ups. “We can’t wait for patients to come to us with symptoms,” said a Legacy physician in a recent interview. “By then, it’s often too late.”

The drug’s arrival also has implications for Houston’s booming clinical trials industry. The city is already a hub for pharmaceutical research, thanks in part to its diverse population and world-class medical institutions. GSK and other drugmakers are likely to set up shop in Houston to conduct post-approval studies on efinopegdutide, which could bring jobs and investment to the city. But it could also raise ethical questions about who gets access to these trials—and who benefits from them. In the past, clinical trials have been criticized for underrepresenting minority populations, even as those same populations bear the brunt of diseases like MASH. Community groups are already pushing for greater transparency and inclusivity in how these trials are conducted, and their voices are likely to grow louder as efinopegdutide moves closer to approval.

Beyond the Pill: The Broader Fight Against MASH in Houston

While efinopegdutide is a major step forward, it’s not a silver bullet. MASH is a disease of lifestyle, and no drug can fully compensate for the effects of poor diet and lack of exercise. That’s why Houston’s public health officials are taking a multi-pronged approach to tackling the disease. At the top of their list? Education. The Houston Health Department has launched a series of campaigns aimed at raising awareness about MASH, targeting everything from school lunch programs to workplace wellness initiatives. One of their most successful efforts has been a partnership with local chefs to create “MASH-friendly” versions of Houston’s iconic dishes—think lighter, healthier takes on gumbo, tacos al pastor, and Vietnamese pho. The idea is to make healthy eating accessible and appealing, rather than preachy or restrictive.

Another key focus is urban planning. Houston’s car-centric design has long been a barrier to physical activity, but that’s starting to change. The city has invested heavily in bike lanes and pedestrian-friendly infrastructure, and groups like BikeHouston are advocating for even more. “We’re not going to solve MASH by telling people to eat less and move more,” said a BikeHouston spokesperson. “We have to make it easier for them to do those things in the first place.” The city is also exploring ways to bring more grocery stores and farmers’ markets to food deserts, though progress has been slow. In the meantime, community gardens and mobile markets are filling the gap, offering fresh produce to residents who might otherwise rely on convenience stores and fast food.

For patients who are already living with MASH, support groups are becoming an increasingly critical part of the treatment landscape. Organizations like the Fatty Liver Foundation have chapters in Houston, offering everything from nutritional counseling to emotional support. These groups are especially vital for patients who feel isolated or overwhelmed by their diagnosis. “MASH is a silent disease,” said one support group leader. “A lot of people don’t even understand they have it until it’s advanced. When they find out, they’re scared, and they don’t know where to turn. We’re here to aid them navigate that.”

Given my background in public health and medical journalism, if this trend impacts you in Houston, here are the three types of local professionals you need to know about—and exactly what to look for when hiring them.

Navigating a MASH diagnosis—or even just the risk of one—can feel overwhelming. But Houston’s healthcare ecosystem is rich with specialists who can help. Here’s how to find the right ones for your needs.

Hepatologists with a Focus on Metabolic Health

Not all liver specialists are created equal. When searching for a hepatologist, look for someone who has experience treating MASH specifically, not just cirrhosis or hepatitis. Many of Houston’s top hepatologists are affiliated with the Texas Medical Center, but don’t overlook community-based practices, especially if you’re looking for a more personalized approach. Here’s what to ask:

• Do you have experience prescribing dual-agonist drugs like efinopegdutide? Even if the drug isn’t yet approved, a hepatologist who’s familiar with the clinical trial data will be better equipped to guide you through your options.
• What’s your approach to non-invasive diagnostics? Liver biopsies are the gold standard, but they’re not always necessary. Ask about alternatives like FibroScan or MRI-based elastography, which are less invasive and increasingly available in Houston.
• How do you integrate lifestyle changes into your treatment plans? The best hepatologists work closely with dietitians, endocrinologists, and even mental health professionals to create a holistic plan. If they’re not mentioning these collaborations, that’s a red flag.

Where to find them: Start with the liver clinics at Houston Methodist, Baylor College of Medicine, or UTHealth. For a more community-based option, check out practices like Liver Specialists of Texas or the Liver Institute at Memorial Hermann.

Registered Dietitians with Expertise in Metabolic Liver Disease

Diet is the cornerstone of MASH management, but not all dietitians are trained in liver-specific nutrition. Look for someone who understands the nuances of metabolic liver disease and can tailor a plan to your cultural preferences—whether that’s Tex-Mex, Southern comfort food, or Vietnamese cuisine. Here’s what to look for:

• Do they have a certification in liver disease nutrition? The Academy of Nutrition and Dietetics offers a specialty certification in this area. It’s not mandatory, but it’s a good sign that they’re up to date on the latest research.
• Can they work with your budget? Healthy eating doesn’t have to be expensive. Ask if they’re familiar with local resources like food banks, community gardens, or SNAP-approved grocery stores. Houston has a wealth of these, but not all dietitians are plugged into them.
• Do they take a non-restrictive approach? MASH diets often focus on reducing sugar and processed foods, but they shouldn’t feel punitive. A good dietitian will help you find satisfying alternatives to your favorite dishes, not just tell you to “eat less.”

Where to find them: Many hepatologists have dietitians on staff, but you can also find independent practitioners through the Houston Academy of Nutrition and Dietetics or local hospitals like Texas Children’s, which has a robust nutrition program.

Endocrinologists Who Specialize in Insulin Resistance

MASH is closely linked to insulin resistance and type 2 diabetes, so an endocrinologist can be a valuable part of your care team. But not all endocrinologists focus on the liver. Look for someone who understands the interplay between metabolic health and liver disease. Here’s what to ask:

• How do you monitor liver health in your diabetic patients? Many endocrinologists focus solely on blood sugar, but the best ones keep an eye on liver enzymes and other markers of MASH.
• Are you familiar with the latest GLP-1 and dual-agonist drugs? These medications are becoming a cornerstone of both diabetes and MASH treatment, so it’s important that your endocrinologist is up to speed.
• Do you collaborate with hepatologists? MASH is a team sport. If your endocrinologist isn’t communicating with your liver specialist, you’re not getting the best care possible.

Where to find them: The Diabetes Research Center at Baylor College of Medicine is a great place to start, as are endocrinology clinics at Houston Methodist and UTHealth. For a more personalized approach, look for private practices that specialize in metabolic health.

Ready to find trusted professionals? Browse our complete directory of top-rated liver and metabolic health experts in the Houston area today.